Rare Gene Mutation Linked to Fatty Liver Disease
A newly discovered rare mutation in the MET gene may be a direct cause of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD). This finding challenges the previous understanding of MASLD as primarily a condition developed from lifestyle and environmental factors, and opens new avenues for diagnosis and treatment.
Understanding MASLD
MASLD is a common liver condition affecting individuals with excess weight, obesity, or other metabolic disorders like type 2 diabetes, high blood pressure, or high cholesterol 1. The condition is characterized by an excessive buildup of fat in the liver. Its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), is projected to become the leading cause of cirrhosis and liver transplants 3.
The Discovery of the MET Gene Mutation
Researchers at the Mayo Clinic’s Center for Individualized Medicine identified the genetic variant through genomic analysis of a father and daughter both diagnosed with MASH, despite lacking typical risk factors such as diabetes or high cholesterol 3. The mutation disrupts the liver’s ability to process fat, leading to inflammation, scarring, and potentially cirrhosis.
The MET gene plays a crucial role in liver repair and fat metabolism. When the gene doesn’t function correctly, fat accumulates within liver cells, triggering inflammation. Over time, this inflammation can progress to fibrosis, scarring, and cirrhosis or even liver cancer.
Prevalence of the Mutation
Analysis of data from the Mayo Clinic’s Tapestry study, a large exome sequencing initiative, revealed that approximately 1% of adults with MASLD carried rare variants in the MET gene 3. Notably, nearly 18% of these variants were located in the same key region identified in the original family, reinforcing the gene’s connection to the disease.
Researchers estimate this finding could potentially impact hundreds of thousands, or even millions, of individuals worldwide who have or are at risk for MASLD 3.
Implications for Diagnosis and Treatment
This discovery underscores the importance of individualized medicine in identifying and understanding complex diseases. The Program for Rare and Undiagnosed Diseases at Mayo Clinic has provided comprehensive genomic testing to over 3,200 patients since 2019, aiding in the diagnosis of difficult-to-diagnose conditions, including rare liver diseases.
Future research will focus on exploring how this discovery can guide the development of targeted treatments and improve the diagnosis and management of MASLD. The identification of this genetic variant provides a new therapeutic target for future investigations.
The Evolution of Terminology
It’s important to note that the condition formerly known as nonalcoholic fatty liver disease (NAFLD) has been renamed to metabolic dysfunction-associated steatotic liver disease (MASLD) to more accurately reflect its causes 4.
Related reading